QuidelOrtho Corporation

NASDAQ:QDEL

Medical - Instruments & Supplies

Healthcare
$9.57 +0.72%

+$0.09 today

Market cap
$656.62M
Beta
0.76
P/E (TTM)
-0.7
EPS (TTM)
-$17.76
52W Low $9.92High $35.58

Volume 2.13M

Average 2.35M

QDEL Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

QuidelOrtho CorporationNASDAQ: QDEL

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 42.6%

Gross margin was 42.6% in Q1 FY2026, down 7.0 pp from a year earlier. On a trailing-twelve-month basis it was 45.0%, down 2.0 pp year over year. Over 3 fiscal years it narrowed by 12.6 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
42.6%-1.7 pp QoQ
Last fiscal yearDec 2025
46.7%+0.4 pp YoY
LTMMar 2026
45.0%-2.0 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-7.0 pp——
1 year+0.4 pp——
3 years-12.6 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
46.7%
Year-over-year change
+0.4pp

Gross Margin vs competitors

How QDEL compares with its peers on the latest reported figures

  • QDEL's LTM Mar 2026 gross margin of 45.0% is the 4th highest of the 9 companies compared; the peer median is 41.2%.
  • Its year-over-year change of -2.0 pp is the 8th highest of 9, against a peer median of -0.5 pp.
  • Over three fiscal years its change of -12.6 pp compares with a peer median of -0.7 pp.
QDEL Competitors Peer median
Gross Margin for QDEL and competitors
Company Period LTM level YoY 3-year change
NNNNAnbio Biotechnology Class A Ordinary SharesFY202587.2% +15.3 pp+33.9 pp
RVTYRevvity, Inc.LTM Jul 202652.1% -1.9 pp-0.1 pp
BIOBio-Rad Laboratories, Inc.LTM Jun 202651.9% -0.9 pp-3.9 pp
QDELQuidelOrtho CorporationLTM Mar 202645.0% -2.0 pp-12.6 pp
TMOThermo Fisher Scientific Inc.LTM Sep 202641.4% +1.0 pp-1.4 pp
OSUROraSure Technologies, Inc.LTM Mar 202641.0% -1.5 pp+3.6 pp
TRIBTrinity Biotech plcLTM Dec 202535.4% +1.4 pp+3.3 pp
DGXQuest Diagnostics IncorporatedLTM Sep 202633.1% -0.2 pp-2.8 pp
OPKOPKO Health, Inc.LTM Mar 202622.7% -6.2 pp-7.6 pp
Peer median (excluding QDEL) 41.2%-0.5 pp-0.7 pp

Competitors are the stored peer set for QDEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Jan 2023
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.7B3.27B3B2.78B2.73B
Cost of Revenue420.3M1.33B1.5B1.5B1.46B
Gross Profit1.28B1.94B1.5B1.29B1.27B
Gross Margin75.3%59.3%49.9%46.2%46.7%
Research & Development95.7M187.9M246.8M218.7M186.2M
Selling, General & Admin239.6M621M763.2M766.8M746.3M
Operating Expenses372.3M1.09B1.36B3.25B2.19B
Depreciation & Amortization52.7M283.6M457.2M453.4M442M
EBITDA953.3M1.09B607M(1.49B)(488.1M)
EBITDA Margin56.1%33.5%20.2%-53.5%-17.9%
Operating Income906M843.7M139.1M(1.96B)(919.2M)
Operating Margin53.3%25.8%4.6%-70.5%-33.7%
Interest Income300K1.3M2.2M00
Interest Expense700K74.5M178.9M188.3M177.6M
Other Income / Expenses(5.7M)(107.8M)(168.2M)(170.6M)(188.5M)
Income Before Tax900.3M735.9M(29.1M)(2.13B)(1.11B)
Pre-Tax Margin53.0%22.5%-1.0%-76.6%-40.6%
Income Tax Expense196.1M187.2M(19M)(79.5M)24.1M
Net Income704.2M548.7M(10.1M)(2.05B)(1.13B)
Net Margin41.5%16.8%-0.3%-73.7%-41.5%
EPS (Basic)16.749.66(0.15)(30.54)(16.69)
EPS (Diluted)16.439.56(0.15)(30.54)(16.69)
Weighted Avg Shares42.08M56.8M66.8M67.2M67.8M
Weighted Avg Shares (Diluted)42.87M57.4M66.8M67.2M67.8M

QuidelOrtho Corporation

NASDAQ:QDEL

Intrinsic Alpha fair value

Locked

Current Price

$9.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.